The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

Now Viewing

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

EP: 13.Insights from the COORDINATE-Diabetes Trial

EP: 14.Coordinating Initiatives to Enhance CRM Care

EP: 15.Implementing CRM Learnings and Utilization of Telehealth

Video content above is prompted by the following:

• What is the clinical and economic burden of Cardiorenal Metabolic Disease (CRM) conditions such as type 2 diabetes, chronic kidney disease, cardiovascular disease and heart failure in the United States?
• How do CRM conditions affect patient quality of life and clinical outcomes?
• How do these conditions impact healthcare resource utilization?
• The CDC has announced that over 42% of adults have obesity; what role does obesity play in the prevalence of CRM conditions in the United States?
• Is this your experience in your practice?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.